Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia

被引：207
作者：
Ceccacci, Elena [1 ,2 ,3 ]
Minucci, Saverio [1 ,2 ,3 ]
机构：
[1] European Inst Oncol, Dept Expt Oncol, Via Adamello 16, I-20139 Milan, Italy
[2] European Inst Oncol, Drug Dev Program, Via Adamello 16, I-20139 Milan, Italy
[3] Univ Milan, Dept Biosci, Via Celoria 26, I-20133 Milan, Italy
来源：
BRITISH JOURNAL OF CANCER | 2016年 / 114卷 / 06期
关键词：
leukaemia; histone deacetylases; HDACi; cancer stem cells; APL; epigenetics; TRANS-RETINOIC ACID; ACETYLATION; HDAC1; DIFFERENTIATION; DISEASES; ROLES;
D O I：
10.1038/bjc.2016.36
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Histone deacetylases (HDACs) are a key component of the epigenetic machinery regulating gene expression, and behave as oncogenes in several cancer types, spurring the development of HDAC inhibitors (HDACi) as anticancer drugs. This review discusses new results regarding the role of HDACs in cancer and the effect of HDACi on tumour cells, focusing on haematological malignancies, particularly acute myeloid leukaemia. Histone deacetylases may have opposite roles at different stages of tumour progression and in different tumour cell sub-populations (cancer stem cells), highlighting the importance of investigating these aspects for further improving the clinical use of HDACi in treating cancer.
引用
收藏
页码：605 / 611
页数：7
相关论文
共 30 条
[1]   Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer [J].
Botrugno, Oronza Antonietta ;
Santoro, Fabio ;
Minucci, Saverio .
CANCER LETTERS, 2009, 280 (02) :134-144
[2]   The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data [J].
Cerami, Ethan ;
Gao, Jianjiong ;
Dogrusoz, Ugur ;
Gross, Benjamin E. ;
Sumer, Selcuk Onur ;
Aksoy, Buelent Arman ;
Jacobsen, Anders ;
Byrne, Caitlin J. ;
Heuer, Michael L. ;
Larsson, Erik ;
Antipin, Yevgeniy ;
Reva, Boris ;
Goldberg, Arthur P. ;
Sander, Chris ;
Schultz, Nikolaus .
CANCER DISCOVERY, 2012, 2 (05) :401-404
[3]   New Insights into the Connection Between Histone Deacetylases, Cell Metabolism, and Cancer [J].
Chiaradonna, Ferdinando ;
Cirulli, Claudia ;
Palorini, Roberta ;
Votta, Giuseppina ;
Alberghina, Lilia .
ANTIOXIDANTS & REDOX SIGNALING, 2015, 23 (01) :30-50
[4]   Cancer Epigenetics: From Mechanism to Therapy [J].
Dawson, Mark A. ;
Kouzarides, Tony .
CELL, 2012, 150 (01) :12-27
[5]   Histone deacetylase inhibitors and genomic instability [J].
Eot-Houllier, Gregory ;
Fulcrand, Geraldine ;
Magnaghi-Jaulin, Laura ;
Jaulin, Christian .
CANCER LETTERS, 2009, 274 (02) :169-176
[6]   Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders [J].
Falkenberg, Katrina J. ;
Johnstone, Ricky W. .
NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (09) :673-691
[7]   Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer [J].
Fraga, MF ;
Ballestar, E ;
Villar-Garea, A ;
Boix-Chornet, M ;
Espada, J ;
Schotta, G ;
Bonaldi, T ;
Haydon, C ;
Ropero, S ;
Petrie, K ;
Iyer, NG ;
Pérez-Rosado, A ;
Calvo, E ;
Lopez, JA ;
Cano, A ;
Calasanz, MJ ;
Colomer, D ;
Piris, MA ;
Ahn, N ;
Imhof, A ;
Caldas, C ;
Jenuwein, T ;
Esteller, M .
NATURE GENETICS, 2005, 37 (04) :391-400
[8]   The many roles of histone deacetylases in development and physiology: implications for disease and therapy [J].
Haberland, Michael ;
Montgomery, Rusty L. ;
Olson, Eric N. .
NATURE REVIEWS GENETICS, 2009, 10 (01) :32-42
[9]   USE OF ALL-TRANS RETINOIC ACID IN THE TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA [J].
HUANG, ME ;
YE, YC ;
CHEN, SR ;
CHAI, JR ;
LU, JX ;
ZHOA, L ;
GU, LJ ;
WANG, ZY .
BLOOD, 1988, 72 (02) :567-572
[10]   Impairment of p53 acetylation, stability and function by an oncogenic transcription factor [J].
Insinga, A ;
Monestiroli, S ;
Ronzoni, S ;
Carbone, R ;
Pearson, M ;
Pruneri, G ;
Viale, G ;
Appella, E ;
Pelicci, P ;
Minucci, S .
EMBO JOURNAL, 2004, 23 (05) :1144-1154
123